Study for Newly Diagnosed patients with Acute Lymphoblastic Lymphoma

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Protocol

NHL16: Study for Newly Diagnosed patients with Acute Lymphoblastic Lymphoma

Diseases

Leukemias / Lymphomas : Acute lymphoblastic leukemia

Description

Lymphomas are cancers that begin in the cells of the immune system. Lymphoblastic lymphoma (LL) is an aggressive (fast-growing) type of non-Hodgkin lymphoma in which too many immature white blood cells, (lymphoblasts) are found in the lymph nodes and the thymus gland. These lymphoblasts may spread quickly to other places in the body. In many ways LL is similar to acute lymphoblastic leukemia (ALL); therefore the treatment for LL is also very similar to treatment used for ALL, and involves many chemotherapy drugs given over several months. The treatments that the patient may receive are called “remission induction, re-intensification, and cranial irradiation or radiation to the brain.

Objectives

The main goal of this study is to try and improve the cure rate of children with lymphoblastic lymphoma.
To learn more about the effects of this treatment (good and bad) in patients with LL.
To learn more about the biology and genetics of this disease by performing research studies on lymphoblastic lymphoma cells, bone marrow and blood.
To learn more about the short term and long term side effects of this treatment (for example, changes in bone density, fertility, and heart function).

Eligibility

Age ≤ 21 years
Written, informed consent and assent following guidelines of the Institutional Review Board, National Cancer Institute (NCI), Food and Drug Administration (FDA), and Office of Human Research Protections (OHRP).
Participants who are pregnant or lactating, with prior therapy or Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. Will not be eligible for the study

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact

Hiroto Inaba, MD. PhD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article